Sensitive and quantitative in vivo analysis of PD‑L1 using magnetic particle imaging and imaging‑guided immunotherapy
文献类型:期刊论文
作者 | Zhengyao Peng1,2![]() ![]() ![]() ![]() |
刊名 | European Journal of Nuclear Medicine and Molecular Imaging
![]() |
出版日期 | 2022 |
卷号 | 50页码:1291-1305 |
英文摘要 | Purpose: The programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) expression correlate with the immunotherapeutic response rate. The sensitive and non-invasive imaging of immune checkpoint biomarkers is favorable for the accurate detection and characterization, image-guided immunotherapy in cancer precision medicine. Magnetic particle imaging (MPI), as a novel and emerging imaging modality, possesses the advantages of high sensitivity, no image depth limitation, positive contrast, and absence of radiation. Hence, in this study, we performed the pioneer investigation of monitoring PD-L1 expression using MPI and the MPI-guided immunotherapy. Methods: We developed anti-PD-L1 antibody (aPDL1)-conjugated magnetic fluorescent hybrid nanoparticles (MFNPs aPDL1) and utilized MPI in combination with fluorescence imaging (FMI) to dynamically monitor and quantify PD-L1 expression in various tumors with different PD-L1 expression levels. The ex vivo real-time polymerase chain reaction (qPCR), western blotting, and immunofluorescence staining analysis were further performed to validate the in vivo imaging observation. Moreover, the MPI was further performed for the guidance of immunotherapy. Results: Our data showed that PD-L1 expression can be specifically and sensitively monitored and quantified using MPI and FMI imaging methods, which were validated by ex vivo qPCR and western blotting analysis. In addition, MPI-guided PD-L1 immunotherapy can enhance the effectiveness of cancer immunotherapy. Conclusion: To our best knowledge, this is the pioneer study to utilize MPI in combination with a newly developed MFNPsaPDL1 imaging probe to dynamically visualize and quantify PD-L1 expression in tumor microenvironment. This imaging strategy may facilitate the clinical optimization of immunotherapy management. |
源URL | [http://ir.ia.ac.cn/handle/173211/56543] ![]() |
专题 | 自动化研究所_中国科学院分子影像重点实验室 |
作者单位 | 1.University of Chinese Academy of Sciences, Beijing 100080, China 2.CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China 3.State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Shenzhen Research Institution of Hunan University, Hunan University, Changsha 410082, China 4.University of Science and Technology of China, Hefei 230026, China 5.Department of Ultrasound, Peking University Third Hospital, Beijing 100191, China 6.Beijing Advanced Innovation Centre for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing 100191, China |
推荐引用方式 GB/T 7714 | Zhengyao Peng,Chang Lu,Guangyuan Shi,et al. Sensitive and quantitative in vivo analysis of PD‑L1 using magnetic particle imaging and imaging‑guided immunotherapy[J]. European Journal of Nuclear Medicine and Molecular Imaging,2022,50:1291-1305. |
APA | Zhengyao Peng.,Chang Lu.,Guangyuan Shi.,Lin Yin.,Xiaolong Liang.,...&Yang Du.(2022).Sensitive and quantitative in vivo analysis of PD‑L1 using magnetic particle imaging and imaging‑guided immunotherapy.European Journal of Nuclear Medicine and Molecular Imaging,50,1291-1305. |
MLA | Zhengyao Peng,et al."Sensitive and quantitative in vivo analysis of PD‑L1 using magnetic particle imaging and imaging‑guided immunotherapy".European Journal of Nuclear Medicine and Molecular Imaging 50(2022):1291-1305. |
入库方式: OAI收割
来源:自动化研究所
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。